The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $10.50

Today's change+0.07 +0.67%
Updated August 28 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $10.50

Today's change+0.07 +0.67%
Updated August 28 4:00 PM -4GMT. Delayed by at least 15 minutes.

Merrimack Pharmaceuticals Inc up (U.S.)$0.07

Merrimack Pharmaceuticals Inc closed up Friday by (U.S.)$0.07 or 0.67% to (U.S.)$10.50. Over the last five days, shares have gained 9.38%, but are down 7.08% for the last year to date. Shares have outperformed the S&P 500 by 49.75% during the last year.

Key company metrics

  • Open(U.S.) $10.31
  • Previous close(U.S.) $10.43
  • High(U.S.) $11.00
  • Low(U.S.) $10.31
  • Bid / Ask-- / --
  • YTD % change-7.08%
  • Volume2,617,481
  • Average volume (10-day)1,540,778
  • Average volume (1-month)1,565,251
  • Average volume (3-month)1,329,368
  • 52-week range(U.S.) $6.38 to (U.S.) $13.84
  • Beta0.99
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.89
Updated August 28 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-83.71%

Although this company's net profit margin is negative, it is above the industry average and implies that Merrimack Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.71%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue37153428
Total other revenue--------
Total revenue37153428
Gross profit--------
Total cost of revenue--------
Total operating expense55453952
Selling / general / administrative12988
Research & development43363144
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-19-30-5-24
Interest income (expense), net non-operating-4-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-23-34-9-28
Income after tax-23-34-9-28
Income tax, total--------
Net income-23-35-10-28
Total adjustments to net income--------
Net income before extra. items-23-35-10-28
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-23-35-10-28
Inc. avail. to common incl. extra. items-23-35-10-28
Diluted net income-23-35-10-28
Dilution adjustment--------
Diluted weighted average shares110107106105
Diluted EPS excluding extraordinary itemsvalue per share-0.21-0.32-0.09-0.27
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.21-0.32-0.09-0.27